Compare AJANTA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DIVIS LABORATORIES AJANTA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 22.2 34.8 63.7% View Chart
P/BV x 3.9 6.7 58.5% View Chart
Dividend Yield % 0.9 0.9 98.6%  

Financials

 AJANTA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
AJANTA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,4221,639 86.7%   
Low Rs8981,115 80.5%   
Sales per share (Unadj.) Rs233.5186.3 125.3%  
Earnings per share (Unadj.) Rs44.051.0 86.3%  
Cash flow per share (Unadj.) Rs52.257.3 91.0%  
Dividends per share (Unadj.) Rs9.0016.00 56.3%  
Dividend yield (eoy) %0.81.2 66.8%  
Book value per share (Unadj.) Rs255.1261.8 97.4%  
Shares outstanding (eoy) m88.02265.47 33.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.07.4 67.2%   
Avg P/E ratio x26.427.0 97.6%  
P/CF ratio (eoy) x22.224.0 92.6%  
Price / Book Value ratio x4.55.3 86.4%  
Dividend payout %20.531.4 65.2%   
Avg Mkt Cap Rs m102,081365,592 27.9%   
No. of employees `0006.811.8 57.4%   
Total wages/salary Rs m4,3075,423 79.4%   
Avg. sales/employee Rs Th3,022.64,175.1 72.4%   
Avg. wages/employee Rs Th633.4457.7 138.4%   
Avg. net profit/employee Rs Th569.11,141.8 49.8%   
INCOME DATA
Net Sales Rs m20,55449,463 41.6%  
Other income Rs m2111,556 13.5%   
Total revenues Rs m20,76551,019 40.7%   
Gross profit Rs m5,66418,718 30.3%  
Depreciation Rs m7211,689 42.7%   
Interest Rs m1235 33.1%   
Profit before tax Rs m5,14318,551 27.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2735,023 25.3%   
Profit after tax Rs m3,87013,527 28.6%  
Gross profit margin %27.637.8 72.8%  
Effective tax rate %24.827.1 91.4%   
Net profit margin %18.827.3 68.8%  
BALANCE SHEET DATA
Current assets Rs m11,81246,501 25.4%   
Current liabilities Rs m3,7768,468 44.6%   
Net working cap to sales %39.176.9 50.8%  
Current ratio x3.15.5 57.0%  
Inventory Days Days77131 59.2%  
Debtors Days Days8286 95.0%  
Net fixed assets Rs m14,39825,797 55.8%   
Share capital Rs m175531 33.0%   
"Free" reserves Rs m22,27768,962 32.3%   
Net worth Rs m22,45269,493 32.3%   
Long term debt Rs m70-   
Total assets Rs m26,96280,383 33.5%  
Interest coverage x444.3531.0 83.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.6 123.9%   
Return on assets %14.416.9 85.3%  
Return on equity %17.219.5 88.5%  
Return on capital %23.026.7 85.8%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m10,68241,238 25.9%   
Fx outflow Rs m2,10212,405 16.9%   
Net fx Rs m8,58028,833 29.8%   
CASH FLOW
From Operations Rs m3,7489,543 39.3%  
From Investments Rs m-2,228-6,854 32.5%  
From Financial Activity Rs m-1,475-2,459 60.0%  
Net Cashflow Rs m45230 19.7%  

Share Holding

Indian Promoters % 73.8 52.0 141.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.8 13.1%  
FIIs % 7.6 19.0 40.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.2 98.8%  
Shareholders   20,968 31,796 65.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON   

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

DR. LAL PATHLABS LTD at All Time High; BSE HEALTHCARE Index Up 1.7% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

DR. LAL PATHLABS LTD share price has hit an all time high at Rs 1,550 (up 4.5%). The BSE HEALTHCARE Index is up by 1.7%. Among the top gainers in the BSE HEALTHCARE Index today are DR. LAL PATHLABS LTD (up 4.5%) and PFIZER (up 1.5%). The top losers include SANOFI INDIA and ABBOTT INDIA .

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Oct 22, 2019 03:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - PFIZER COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS